Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.10.2011 | Brief Report

MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism

verfasst von: Muhua Yang, Yuan Yao, Gabriel Eades, Yongshu Zhang, Qun Zhou

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

NF-E2-related factor 2 (Nrf2) is an important transcription factor involved in antioxidant response. Nrf2 binds antioxidant response elements (ARE) within promoters of genes encoding detoxification enzymes (e.g., NAD (P) H-quinone oxidoreductase 1 (NQO1)) leading to their transcriptional activation. Nrf2 function is regulated post-translationally by its negative regulator Kelch-like ECH-associated protein 1 (Keap1) that binds Nrf2 and induces cytoplasmic Nrf2 degradation. Our present studies provide new evidence that Nrf2 expression can be regulated by a Keap1-independent mechanism. Here, we utilized breast epithelial cells to explore the impact of microRNA (miRNA) on Nrf2 expression. We found that Nrf2 mRNA levels are reversibly correlated with miR-28 expression and that ectopic expression of miR-28 alone reduces Nrf2 mRNA and protein levels. We further investigated the molecular mechanisms by which miR-28 inhibits Nrf2 mRNA expression. Initially, the ability of miR-28 to regulate the 3′ untranslated region (3′UTR) of Nrf2 mRNA was evaluated via luciferase reporter assay. We observed that miR-28 reduces wild-type Nrf2 3′UTR luciferase reporter activity and this repression is eliminated upon mutation of the miR-28 targeting seed sequence within the Nrf2 3′UTR. Moreover, over-expression of miR-28 decreased endogenous Nrf2 mRNA and protein expression. We also explored the impact of miR-28 on Keap1-Nrf2 interactions and found that miR-28 over-expression does not alter Keap1 protein levels and has no effect on the interaction of Keap1 and Nrf2. Our findings, that miR-28 targets the 3′UTR of Nrf2 mRNA and decreases Nrf2 expression, suggest that this miRNA is involved in the regulation of Nrf2 expression in breast epithelial cells.
Literatur
1.
Zurück zum Zitat Yu S, Kong A (2007) Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets 7:416–424PubMedCrossRef Yu S, Kong A (2007) Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets 7:416–424PubMedCrossRef
2.
Zurück zum Zitat Fields WR, Morrow CS, Doehmer J et al (1999) Expression of stably transfected murine glutathione S-transferase A3–3 protects against nucleic acid alkylation and cytotoxicity by aflatoxin B1 in hamster V79 cells expressing rat cytochrome P450–2B1. Carcinogenesis 20:1121–1125PubMedCrossRef Fields WR, Morrow CS, Doehmer J et al (1999) Expression of stably transfected murine glutathione S-transferase A3–3 protects against nucleic acid alkylation and cytotoxicity by aflatoxin B1 in hamster V79 cells expressing rat cytochrome P450–2B1. Carcinogenesis 20:1121–1125PubMedCrossRef
3.
Zurück zum Zitat Henderson CJ, Smith AG, Ure J et al (1998) Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 95:5275–5280PubMedCrossRef Henderson CJ, Smith AG, Ure J et al (1998) Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 95:5275–5280PubMedCrossRef
4.
Zurück zum Zitat Ramos-Gomez M, Kwak MK, Dolan PM et al (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98:3410–3415PubMedCrossRef Ramos-Gomez M, Kwak MK, Dolan PM et al (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98:3410–3415PubMedCrossRef
5.
Zurück zum Zitat Ramos-Gomez M, Dolan P, Itoh K et al (2003) Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24:461–467PubMedCrossRef Ramos-Gomez M, Dolan P, Itoh K et al (2003) Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24:461–467PubMedCrossRef
6.
Zurück zum Zitat McMahon M, Itoh K, Yamamoto M et al (2001) The Cap’n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61:3299–3307PubMed McMahon M, Itoh K, Yamamoto M et al (2001) The Cap’n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61:3299–3307PubMed
7.
Zurück zum Zitat Harvey CJ, Thimmulappa RK, Singh A et al (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46:443–453PubMedCrossRef Harvey CJ, Thimmulappa RK, Singh A et al (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46:443–453PubMedCrossRef
8.
Zurück zum Zitat Barve A, Khor T, Nair S et al (2009) Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 124:1693–1699PubMedCrossRef Barve A, Khor T, Nair S et al (2009) Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 124:1693–1699PubMedCrossRef
9.
Zurück zum Zitat Acharya A, Das I, Chandhok D et al (2010) Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3(1):23–34PubMedCrossRef Acharya A, Das I, Chandhok D et al (2010) Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3(1):23–34PubMedCrossRef
10.
Zurück zum Zitat Hsieh T, Elangovan S, Wu J (2010) Differential suppression of proliferation in MCF-7 and MDA-MB-231 breast cancer cells exposed to alpha-, gamma- and delta-tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes. Anticancer Res 30:4169–4176PubMed Hsieh T, Elangovan S, Wu J (2010) Differential suppression of proliferation in MCF-7 and MDA-MB-231 breast cancer cells exposed to alpha-, gamma- and delta-tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes. Anticancer Res 30:4169–4176PubMed
11.
Zurück zum Zitat Yao Y, Brodie AMH, Davidson N et al (2010) Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 124:585–591PubMedCrossRef Yao Y, Brodie AMH, Davidson N et al (2010) Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 124:585–591PubMedCrossRef
12.
Zurück zum Zitat Singh A, Misra V, Thimmulappa R et al (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Medicine 3:e420PubMedCrossRef Singh A, Misra V, Thimmulappa R et al (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Medicine 3:e420PubMedCrossRef
13.
Zurück zum Zitat Ohta T, Iijima K, Miyamoto M et al (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68:1303–1309PubMedCrossRef Ohta T, Iijima K, Miyamoto M et al (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68:1303–1309PubMedCrossRef
14.
Zurück zum Zitat Dinkova-Kostova A, Holtzclaw WD, Cole R et al (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99:11908–11913PubMedCrossRef Dinkova-Kostova A, Holtzclaw WD, Cole R et al (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99:11908–11913PubMedCrossRef
15.
Zurück zum Zitat Wakabayashi N, Dinkova-Kostova A, Holtzclaw WD et al (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101:2040–2045PubMedCrossRef Wakabayashi N, Dinkova-Kostova A, Holtzclaw WD et al (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101:2040–2045PubMedCrossRef
16.
Zurück zum Zitat Kobayashi M, Yamamoto M (2006) Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46:113–140PubMedCrossRef Kobayashi M, Yamamoto M (2006) Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 46:113–140PubMedCrossRef
17.
Zurück zum Zitat Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244(1):37–42PubMedCrossRef Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244(1):37–42PubMedCrossRef
18.
Zurück zum Zitat Kaspar J, Niture S, Jaiswal A (2009) Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47:1304–1309PubMedCrossRef Kaspar J, Niture S, Jaiswal A (2009) Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47:1304–1309PubMedCrossRef
19.
Zurück zum Zitat Miao W, Hu L, Scrivens PJ et al (2005) Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem 280:20340–20348PubMedCrossRef Miao W, Hu L, Scrivens PJ et al (2005) Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem 280:20340–20348PubMedCrossRef
20.
Zurück zum Zitat Kwak M, Itoh K, Yamamoto M, Kensler T (2002) Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 22:2883–2892PubMedCrossRef Kwak M, Itoh K, Yamamoto M, Kensler T (2002) Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 22:2883–2892PubMedCrossRef
21.
Zurück zum Zitat Wang X, Zhang D (2009) Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational level. PLoS ONE 4:e5492PubMedCrossRef Wang X, Zhang D (2009) Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational level. PLoS ONE 4:e5492PubMedCrossRef
22.
Zurück zum Zitat Yu S, Khor T, Cheung K et al (2010) Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS ONE 5:e8579PubMedCrossRef Yu S, Khor T, Cheung K et al (2010) Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS ONE 5:e8579PubMedCrossRef
23.
Zurück zum Zitat Filipowicz W, Bhattacharyya S, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102–114PubMedCrossRef Filipowicz W, Bhattacharyya S, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9:102–114PubMedCrossRef
24.
Zurück zum Zitat Winter J, Jung S, Keller S et al (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11:228–234PubMedCrossRef Winter J, Jung S, Keller S et al (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11:228–234PubMedCrossRef
25.
26.
Zurück zum Zitat Voorhoeve PM, Agami R (2007) Classifying microRNAs in cancer: the good, the bad and the ugly. Biochim Biophys Acta 1775:274–282PubMed Voorhoeve PM, Agami R (2007) Classifying microRNAs in cancer: the good, the bad and the ugly. Biochim Biophys Acta 1775:274–282PubMed
27.
Zurück zum Zitat Sangokoya C, Telen M, Chi J (2010) microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 116:4338–4348PubMedCrossRef Sangokoya C, Telen M, Chi J (2010) microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 116:4338–4348PubMedCrossRef
28.
Zurück zum Zitat Rosenfeld N, Aharonov R, Meiri E et al (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462–469PubMedCrossRef Rosenfeld N, Aharonov R, Meiri E et al (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462–469PubMedCrossRef
29.
Zurück zum Zitat Corcoran C, Friel A, Duffy M et al (2011) Intracellular and extracellular microRNAs in breast cancer. Clin Chem 57:18–32PubMedCrossRef Corcoran C, Friel A, Duffy M et al (2011) Intracellular and extracellular microRNAs in breast cancer. Clin Chem 57:18–32PubMedCrossRef
30.
31.
Zurück zum Zitat Gottardo F, Liu C, Ferracin M et al (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392PubMedCrossRef Gottardo F, Liu C, Ferracin M et al (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392PubMedCrossRef
32.
Zurück zum Zitat Malzkorn B, Wolter M, Liesenberg F et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539–550PubMedCrossRef Malzkorn B, Wolter M, Liesenberg F et al (2010) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20:539–550PubMedCrossRef
33.
Zurück zum Zitat Girardot M, Pecquet C, Boukour S et al (2010) miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 116:437–445PubMedCrossRef Girardot M, Pecquet C, Boukour S et al (2010) miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 116:437–445PubMedCrossRef
34.
Zurück zum Zitat Fan W, Tang Z, Chen D et al (2010) Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 6:614–621CrossRef Fan W, Tang Z, Chen D et al (2010) Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 6:614–621CrossRef
35.
Zurück zum Zitat Furukawa M, Xiong Y (2005) BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25:162–171PubMedCrossRef Furukawa M, Xiong Y (2005) BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25:162–171PubMedCrossRef
36.
Zurück zum Zitat Zhou H, Mazan-Mamczarz K, Martindale J et al (2010) Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res 38:3619–3631PubMedCrossRef Zhou H, Mazan-Mamczarz K, Martindale J et al (2010) Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res 38:3619–3631PubMedCrossRef
37.
Zurück zum Zitat Agoston A, Argani P, Yegnasubramanian S et al (2005) Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 280:18302–18310PubMedCrossRef Agoston A, Argani P, Yegnasubramanian S et al (2005) Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 280:18302–18310PubMedCrossRef
38.
Zurück zum Zitat Kensler T, Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31:90–99PubMedCrossRef Kensler T, Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31:90–99PubMedCrossRef
39.
Zurück zum Zitat Xu W, Li J, Fan L et al (2009) Expressions of bcl-6, lpp and miR-28 genes in diffuse large B cell lymphoma cell lines. Zhong Guo Shi Yan Xue Ye Xue Za Zhi 17:83–87 Xu W, Li J, Fan L et al (2009) Expressions of bcl-6, lpp and miR-28 genes in diffuse large B cell lymphoma cell lines. Zhong Guo Shi Yan Xue Ye Xue Za Zhi 17:83–87
40.
Zurück zum Zitat Li L, Zhang Z, Liu Y et al (2010) DNA microarrays-based microRNA expression profiles derived from formalin-fixed paraffin-embedded tissue blocks of squammous cell carcinoma of larynx. Zhong Hua Bing Li Xue Za Zhi 39:391–395 Li L, Zhang Z, Liu Y et al (2010) DNA microarrays-based microRNA expression profiles derived from formalin-fixed paraffin-embedded tissue blocks of squammous cell carcinoma of larynx. Zhong Hua Bing Li Xue Za Zhi 39:391–395
41.
Zurück zum Zitat Eulalio A, Huntzinger E, Izaurralde E (2008) Getting to the root of miRNA-mediated gene silencing. Cell 132:9–14PubMedCrossRef Eulalio A, Huntzinger E, Izaurralde E (2008) Getting to the root of miRNA-mediated gene silencing. Cell 132:9–14PubMedCrossRef
42.
Zurück zum Zitat Nottrott S, Simard M, Richter J (2006) Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol 13:1108–1114PubMedCrossRef Nottrott S, Simard M, Richter J (2006) Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol 13:1108–1114PubMedCrossRef
43.
Zurück zum Zitat Klaunig J, Kamendulis L, Hocevar B (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38:96–109PubMedCrossRef Klaunig J, Kamendulis L, Hocevar B (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38:96–109PubMedCrossRef
44.
Zurück zum Zitat Kwak M, Kensler T (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66–76PubMedCrossRef Kwak M, Kensler T (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66–76PubMedCrossRef
45.
Zurück zum Zitat Rachakonda G, Sekhar KR, Jowhar D et al (2010) Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 29:3703–3714PubMedCrossRef Rachakonda G, Sekhar KR, Jowhar D et al (2010) Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 29:3703–3714PubMedCrossRef
46.
Zurück zum Zitat Havens C, Ho A, Yoshioka N et al (2006) Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol 26:4701–4711PubMedCrossRef Havens C, Ho A, Yoshioka N et al (2006) Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol 26:4701–4711PubMedCrossRef
Metadaten
Titel
MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism
verfasst von
Muhua Yang
Yuan Yao
Gabriel Eades
Yongshu Zhang
Qun Zhou
Publikationsdatum
01.10.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1604-1

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.